Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

Lattice Biologics Ltd. (LBLTF)

0.0001
0.0000
(0.00%)
At close: April 23 at 4:00:00 PM EDT
Loading Chart for LBLTF
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0001
  • Volume 1,000
  • Avg. Volume 0
  • Market Cap (intraday) 4.067M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; and acellular dermal matrix that provides a natural collagen tissue scaffold that promotes cellular ingrowth, tissue vascularization, and regeneration The company also develops amniotic fluid-based products, such as AmnioBoost and AmnioBlast. In addition, it sells traditional allografts for multi-disciplinary applications, including orthopedics, neurology, podiatry, and oral/maxillofacial. The company is headquartered in Belgrade, Montana.

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: LBLTF

View More

Performance Overview: LBLTF

Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LBLTF
0.00%
S&P 500 (^GSPC)
6.75%

1-Year Return

LBLTF
0.00%
S&P 500 (^GSPC)
8.15%

3-Year Return

LBLTF
99.44%
S&P 500 (^GSPC)
28.40%

5-Year Return

LBLTF
99.86%
S&P 500 (^GSPC)
93.35%

Compare To: LBLTF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LBLTF

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -61.08%

  • Return on Assets (ttm)

    -24.95%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.56M

  • Net Income Avi to Common (ttm)

    -951.65k

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: LBLTF

View More

Company Insights: LBLTF

Research Reports: LBLTF

View More

People Also Watch